Khuloud Bajbouj1,2*
Abeer Al-Ali2
Jasmin Shafarin2
Lina Sahnoon2
Ahmad Sawan1
Ahmed Shehada1
Walaaeldin Elkhalifa1
Maha Saber-Ayad1,2,3
Jibran Sualeh Muhammad1,2
Adel B. Elmoselhi1,2,4
Salman Y. Guraya1,2
Mawieh Hamad2,5- 1College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
- 2Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates
- 3Medical Pharmacology Department, Cairo University, Cairo, Egypt
- 4Department of Physiology, Michigan State University, East Lansing, MI, United States
- 5College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
Background: Numerous clinical and experimental observations have alluded to the substantial anti-neoplastic role of vitamin D in breast cancer (BC), primarily by inducing apoptosis and affecting metastasis. Tumor progression and resistance to chemotherapy have been linked to vasculogenic mimicry (VM), which represents the endothelial-independent formation of microvascular channels by cancer cells. However, the effect of vitamin D on VM formation in BC has not been thoroughly investigated. This study examined the impact of 1α,25-dihydroxyvitamin D3 (calcitriol), the active form of vitamin D, on the expression of major factors involved in BC migration, invasion, and VM formation.
Experimental Methods: Publicly available transcriptomic datasets were used to profile the expression status of the key VM markers in vitamin D-treated BC cells. The in silico data were validated by examining the expression and activity of the key factors that are involved in tumor progression and MV formation in hormone-positive MCF-7 and aggressive triple‐negative MDA-MB-231 BC cells after treatment with calcitriol.
Results and Discussions: The bioinformatics analysis showed that tumor VM formation-enriched pathways were differentially downregulated in vitamin D-treated cells when compared with control counterparts. Treatment of BC cells with calcitriol resulted in increased expression of tissue inhibitors of metalloproteinases (TIMPs 1 and 2) and decreased content and gelatinolytic activity of matrix metalloproteinases (MMPs 2 and 9). Furthermore, calcitriol treatment reduced the expression of several pro-MV formation regulators including vascular endothelial growth factor (VEGF), tumor growth factor (TGF-β1), and amphiregulin. Eventually, this process resulted in a profound reduction in cell migration and invasion following the treatment of BC cells with calcitriol when compared to the controls. Finally, the formation of VM was diminished in the aggressive triple‐negative MDA-MB-231 cancer cell line after calcitriol treatment.
Conclusion: Our findings demonstrate that vitamin D mediates its antitumor effects in BC cells by inhibiting and curtailing their potential for VM formation.
Introduction
Breast cancer (BC) is the most common type of cancer among women worldwide (1). Epidemiological data from 1990 to 2017 have signaled that the incidence of BC has been rising in all geographical regions of the world, especially in the Middle East and North Africa (MENA), South Asia, and Latin America (2). The staggering upsurge in the incidence of BC continues to pose a serious health challenge to the global healthcare authorities. One of the major hurdles faced by healthcare professionals remains the heterogeneous and complex nature of BC (3, 4). To add to its complexity, the breast tissue, being subject to a diverse set of conflicting hormonal and growth signals, is more prone to neoplastic transformations as opposed to other biologically less dynamic tissues.
It is well established that classical angiogenesis, initiated by endothelial blood vessels, supports tumor growth and metastasis. However, in 1991, Maniotis et al. reported an endothelial-independent vascularization formation by tumor cells, a process described as vasculogenic mimicry (VM). The VM contributes to tumor proliferation and invasion in many types of cancers through the upregulation of several proteins, including matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor (VEGF), and growth factor-β1 (TGF-β1) (5–9). Despite the technological and clinical advances in BC management and therapeutics, VM has been shown to be associated with aggressive behaviors of tumor progression and perfusions (10, 11), leading to unsatisfactory and adverse clinical outcomes (12, 13). Therefore, there is an ever-growing need for the development of VM-specific therapeutic strategies for BC.
In the last two decades, a plethora of investigational studies have explored the status of VM formation and its role in the prognosis and clinicopathological parameters of BC. For instance, a study on more than 1,200 patients with BC showed a positive correlation between the increased VM positivity and larger tumor size, the propensity for metastasis, differentiation grade, and poor prognosis (14). Considering the characteristics of breast molecular subtypes and hormone-positive BC expression of VEGF (15), research has shown that cancer progression can be arrested or slowed down by targeting TGF-β1, MMP-2, and MMP-9 when irradiated by a proton beam (7). Additionally, the ERα-positive cell line MCF-7 has been reported to induce VM upon exposure to the VM mediator, interleukin 1β (7). Furthermore, aggressive triple‐negative MDA-MB-231 BC cells readily exhibit VM phenotypes by forming tubular-like structures in the gel matrix (16).
Vitamin D is known to undergo a two-step metabolism in both the liver and kidney to produce the biologically active form calcitriol, which binds to the vitamin D receptor (VDR) and allows it to perform a variety of physiological roles (17, 18). The calcitriol, in turn, operates by binding to the intracellular VDRs in target cells. VDRs, first reported in the BC cell lines in 1979, represent a family of nuclear steroid receptors that, when engaged, can regulate the expression of greater than 200 genes involved in cell growth and differentiation and has been shown to greatly affect breast tissue kinetics (19, 20), by acting as ligand-activated transcription factors (21). Numerous extrarenal tissues in the body including breast tissue cells contain 1-α-hydroxylase enzymes needed to produce the active vitamin D metabolite 1,25(OH)2D from circulating 25(OH)D (22). Previous work has shown that the locally synthesized 1,25(OH)2D binds to VDRs expressed in breast epithelial tissue and modulates the expression of several genes (23). Breast tissue cells also contain 24-hydroxylase enzyme (CYP24) that transforms 1,25(OH)2D into the less active metabolites (24,25-dihydroxyvitamin D3 and 1,24,25-trihydroxyvitamin D3). Hence, breast tissue cells possess all key components to produce vitamin D and transduce and respond to vitamin D-dependent signals (23, 24). Numerous observational, in vitro, and animal model-based studies have elaborated on the protective effects of vitamin D signaling against the development and progression of BC (25–34).
The clinical administration of calcitriol or vitamin D analogs has been investigated in several epidemiological and experimental studies that have indicated its effective role in the prevention and treatment of a wide spectrum of malignancies (35, 36). Calcitriol has been shown to suppress cell proliferation and tumor progression by altering multiple mechanisms (37, 38). It inhibits cancer stem-like cells and induces triple-negative BC differentiation (39). Additionally, it has been shown that calcitriol exhibits anti-proliferative concentrations in both MCF-7 and MDA-MB-231 BC cell lines (40). We have recently reported that calcitriol could exert significant anticancer effects by disrupting cellular iron homeostasis (41). Interestingly, studies have analyzed the role of calcitriol in angiogenesis. It has been shown that calcitriol treatment would enhance angiogenesis in in vitro and in vivo lab-based experiments (42–45). In sharp contrast, the impact of calcitriol on vascularization has been shown to decrease endothelial cell growth and attenuate vessel formation (46, 47). In this perspective, a recent study has demonstrated the ability of calcitriol to inhibit tumor neovascularization and metastasis in BC (48). Collectively, more investigations are essential to investigate the antineoplastic role of vitamin D in BC. Therefore, this study was designed to investigate the anti-metastatic role of vitamin D and its association with the modulation of VM factors in BC cells.
Materials and Methods
Bioinformatics Analysis of Publicly Available Transcriptomic Data Resources
In silico bioinformatics were used to identify major pathways that are associated with vitamin D in BC cells. The microarray dataset of GSE27220 (41) was obtained from the National Centre for Biotechnology Information Gene Expression Omnibus (NCIB GEO, https://www.ncbi.nlm.nih.gov/geo). The transcriptional effect of 1,25-dihydroxyvitamin D3 was explored at physiological and supraphysiological (pharmacological) concentrations (100 nM) in the BC MCF-7 cell line. The differentially expressed genes (DEGs) were identified using the GEO2R online tool (https://www.ncbi.nlm.nih.gov/geo/info/geo2r.html), which employs LIMMA (Linear Models for MicroArray data) and GEOquery packages from the Bioconductor for group comparisons. Gene set enrichment analysis was carried out using "Enrichr" tool (49).
Cells and Treatment Protocols
Human BRCA cell lines MCF-7 and MDA-MB-231 from the American Type Culture Collection (Manassas, VA, USA) were used throughout the study. Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 μg/ml of insulin, 1 mM of sodium pyruvate, 1 mM of non-essential amino acids, 4 mM of glutamine, 10% fetal calf serum, and antibiotics (penicillin/streptomycin) at 37°C and 5% CO2. Cells were seeded at 0.5–1 × 105 cells/ml in 25-cm flasks at ~70% confluency, and then cells were treated with various concentrations of calcitriol (25-hydroxyvitamin D; the active form of vitamin D) (2551; Tocris Bioscience, Minneapolis, MN, USA) for several time points. Control cultures were either left untreated or treated with equal volumes of dimethyl sulfoxide (DMSO) as the vehicle.
Quantitative Real-Time Reverse Transcription–PCR
The cDNA was synthesized from 1 μg of total RNA using the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s protocol. RT-PCR was performed using 1:l of complementary DNA (cDNA), specific primers for various tissue inhibitors of metalloproteinases (TIMPs) [TIMP1-forward: 5′-CGCAGCGAGGAGGTTTCTCAT-3′, TIMP1-reverse: 5′-GGCAGTGATGTGCAAATTTCC-3′, TIMP2-forward: 5′-GGCGTTTTGCAATGCAGATGTAG-3′, TIMP2-reverse: 5′-CACAGGAGCCGTCACTTCTCTTG-3′], SYBR® Green I, and an iCycler Thermal Cycler. Expression levels of target human genes were normalized to GAPDH expression [GAPDH forward-5′-ATCACCATCTTCCAGGAGCGAGATC-3′, GAPDH reverse-5′-GGCAGAGATGATGACCCTTTTGGC-3′].
Western Blotting Analysis
Cells were lysed in ice-cold NP-40 lysis buffer (1.0% NP-40, 150 mM of NaCl, and 50 mM of Tris-Cl, pH 8.0) containing protease cocktail inhibitor tablets (Cat. No. S8830; Sigma, Darmstadt, Germany). Whole-cell lysate protein concentrations were quantified using the standard Bradford method. Lysate proteins were separated by 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto a nitrocellulose membrane. The membrane was blocked by 5% skimmed milk powder dissolved for 1 h at room temperature, washed with TBST, and reacted with primary immunoglobulin G (IgG) unlabeled antibodies (Pro-VM formation Sampler Kit, Cell Signaling Technology, Danvers, MA, USA) at 1:1,000 dilution overnight at 4°C. The secondary (anti-mouse and anti-rabbit) antibodies (Cat. No. 7076 and 7074) were then reacted with the membrane at 1:1,000 dilutions for 1 h at room temperature. The secondary (anti-IgG) antibody (Cell Signaling) was reacted with the membrane at 1:5,000 dilution for 1 h at room temperature. Chemiluminescence was detected using the enhanced chemiluminescence (ECL) kit (Cat. No. #1705061; Bio-Rad Laboratories, Hercules, CA, USA). Later, the protein band quantification was carried out using the Bio-Rad Image Lab software (ChemiDoc™ Touch Gel and Western Blot Imaging System; Bio-Rad). Then β-actin (Sigma) was used as a normalization control, and values of control (untreated) samples were defined as 1.00; values of experimental samples were quantified relative to those of control.
Matrix Metalloproteinase Activity Assay
Cells treated with and without calcitriol were assayed for MMP activity using the human MMP-2 (Cat. No. ab100606, Abcam, Cambridge, UK) and MMP-9 assay kits (Cat. No. ab100610, Abcam, Cambridge, UK); supernatants of calcitriol-treated and control cells were separately collected at 24 and 48 h posttreatment. As per the manufacturer’s protocol, 10 µg/ml of trypsin was added and incubated for 1.5 h. A trypsin inhibitor was then added at 100 µg/ml concentration for 15 min. MMP substrate solution with test components was then added to the microplate along with the controls. Plates were read at room temperature and 412-nm wavelength absorbance, and data were tabulated and analyzed.
Proteome Profiler Array
Fifty-five angiogenesis-related proteins were measured in MCF-7 and MDA-MB-231 cells using the Human Angiogenesis (Pro-VM formation mediators) Array Kit (Cat. No. ARY007; R&D Systems, Minneapolis, MN, USA). Whole-cell lysate protein concentrations were quantified using the standard Bradford method. Four nitrocellulose membranes, each containing 55 different capture antibodies, were blocked by Array Buffer 6 for 1 h at room temperature. Lysate aliquots containing 300 μg of protein were prepared with Array Buffer 4 and 20 μl of Detection Antibody Cocktail. Samples were then loaded onto the membrane overnight at 2°C–8°C. Chemiluminescence was detected by streptavidin–horseradish peroxidase (HRP) methods using the dilution factor suggested by the manufacturer. Protein dot quantification was done using the Bio-Rad Image Lab software (ChemiDoc™ Touch Gel and Western Blot Imaging System; Bio-Rad). Reference spots were used as a normalization control; values of control (untreated) samples were defined as 1.00; values of experimental samples were quantified relative to that of control.
Cell Migration Assay
Cells treated with and without calcitriol were assayed using Cell Migration/Chemotaxis Assay Kit (96-well, Abcam) to measure the migration level according to the manufacturer’s instructions. Cell Migration/Chemotaxis Assay Kit (96-well, Abcam) utilizes a Boyden chamber, where the cells migrate through a semi-permeable membrane under different stimuli. Cell migration was analyzed directly by reading fluorescence (Ex/Em = 530/590 nm) in a plate reader. Prior to the assay, cells were prepared by starving the cells for 18–24 h in serum-free media. A cell migration assay containing the desired chemoattractant was prepared in the bottom chamber. The cell migration chamber was incubated at 37°C in a CO2 incubator for 2–48 h. The standard curve for each cell type was prepared. The migrated cells were separated. The cell dye was added, and the migrated cells were quantified.
Cell Invasion Assay
Calcitriol-treated and control cells were assayed using the Cell Invasion Assay kit (Basement Membrane, 96-well, ab235697, Abcam, USA) to measure the invasion level according to the manufacturer’s instructions. Cell Invasion Assay (Basement Membrane, 96-well, Abcam) utilizes a Boyden chamber coated with Basement Membrane Extract (BME), where the cells invade the matrix and then migrate through a semi-permeable membrane in the Boyden chamber in response to stimulants or inhibitory compounds. Cell invasion was analyzed directly by reading fluorescence (Ex/Em = 530/590 nm) in a plate reader. Prior to the assay, cells were prepared by starving the cells for 18–24 h in serum-free media. A cell invasion assay containing the desired chemoattractant was prepared in the bottom chamber. The cell invasion chamber was incubated at 37°C in a CO2 incubator for 2–48 h. The standard curve for each cell type was prepared. Later, the cells were washed. The cell dye was added, and then cells were incubated at 37°C in a CO2 incubator for 60 min. The cell invasion chamber was disassembled, and the invading cells were quantified.
Tube Formation Assay
Cells were seeded in 96-well plates at a density of 2 × 10 cells per well in the matrix solution and then processed according to the manufacturer’s protocol (Abcam, UK). Several images were captured by a phase-contrast inverted microscope at ×10 magnification.
Statistical Analysis
Data were statistically analyzed by the two-way ANOVA with Tukey’s multiple comparisons test for multiple comparisons of values; a p < 0.05 was considered statistically significant. Data fitting and pictorial graphs were presented using the GraphPad Prism 8 software (San Diego, CA, USA).
Results
Vitamin D Signaling Downregulates “TGF-β Regulation of Extracellular Matrix” and “Vasculogenic Mimicry-Related” Pathways in BC Cells
Bioinformatics analysis using a publicly available dataset of MCF-7 cells treated with calcitriol showed that several pathways were subject to differential regulation by vitamin D signaling (Figure 1A). “TGF-β regulation of extracellular matrix” and “VM-related” pathways are shown in Figures 1B, C as the top downregulated pathways. They were also selected for biological validation. The signaling pathways, which are upregulated in calcitriol-treated MCF-7 cells, relative to the controls are shown in Supplementary Table 1. These data show the adjusted p-value, odds ratio, and the combined score for each pathway. It also shows the DEG related to each pathway.
Figure 1 Vitamin D signaling differentially regulates key VM-related genes and signaling pathways in BC cells: with the use of Enrichr tool, a publicly available dataset of MCF-7 cells treated with pharmacological doses of 1,25-dihydroxycholecalciferol (vitamin D3) (GSE27220) was used to identify differentially regulated genes and pathways. MCF-7 cells used in generating these data were left untreated or treated with 100 nM of 1,25-dihydroxycholecalciferol (calcitriol) (treated, n = 5; control, n = 5). (A) Top differentially downregulated pathways. (B) Pathways selected for biological validation. (C) Input genes plotted versus enriched terms. VM, vasculogenic mimicry; BC, breast cancer.
Vitamin D Influences the Levels and Activity of Tissue Inhibitors of Metalloproteinases and Matrix Metalloproteinases
The effect of vitamin D was measured by analyzing the level of TIMPs and MMPs on MCF-7 and MDA-MB-231 cell lines treated with 10 µM of calcitriol for 24 and 48 h. As demonstrated in Figure 2A, the expression level of TIMP1 increased at both 24 and 48 h in MCF-7-treated cells compared with the control. Moreover, expression of TIMP2 also increased 24 h posttreatment, while a reduction was observed at 48 h compared to the control in MCF-7 cells. However, expression levels of both TIMP1 and TIMP2 showed a significant upregulation in MDA-MB-231 posttreatment at 24 h. Reduction of TIMP1 and non-significant TIMP2 upregulation was observed 48 h posttreatment. The treatment of MCF-7 and MDA-MB-231 cells with 10 µM of vitamin D showed a significant effect on the expression of TIMPs and MMPs at protein levels. As shown in Figure 2B, TIMP1 levels were significantly decreased in MCF-7 at 24 h, while an increase was observed at 48 h posttreatment. However, TIMP2 expression was increased at both 24 and 48 h. Furthermore, the expression levels of both MMP-2 and MMP-9 proteins were decreased in MCF-7 at 24 and 48 h posttreatment. However, the expression levels of both TIMP1 and TIMP2 were significantly increased in MDA-MB-231 at both 24 and 48 h post vitamin D treatment, whereas a decrease of MMP-2 and MMP-9 at both time points posttreatment was observed.
Figure 2 Expression levels of TIMPs and MMPs in MCF-7 and MDA-MB-231 cell lines treated with calcitriol for 24 and 48 h. (A) qRT-PCR analysis of TIMP1 and TIMP2 gene expression levels. (B) Western bolt analysis showing TIMP1, TIMP2, MMP-2, and MMP-9 protein levels in MCF-7 and MDA-MB-231 cells treated with 10 µM of calcitriol and cultured for 24 and 48 h. (B) ***p < 0.01, determined using unpaired two-tailed Student’s t-test. Representative immunoblots depicting protein levels where β-actin was used as loading control. (C) Quantitative analysis of relative protein band density after normalization to β-actin and compared in MCF-7 and MDA-MB-231 cells treated with 10 µM of calcitriol and cultured for 24 and 48 h and compared to the control. (*) represents statistically significant change in viability between the indicated treatment groups at given time points. **p < 0.05; ***p < 0.001. TIMPs, tissue inhibitors of metalloproteinases; MMPs, matrix metalloproteinases.
Vitamin D Reduces Activities of MMP-2 and MMP-9
The effect of vitamin D on MMP-2 and MMP-9 activity levels is illustrated in Figure 3. As illustrated in Figure 3A, the activity levels of MMP-2 in MCF-7 were decreased at both 24- and 48-h posttreatment. At the same time, the activity levels of MMP-9 were reduced at both time points after treatment (Figure 3C). However, the activity significantly decreased in MDA-MB-231 cells at both 24 and 48 h as compared with the control (Figure 3B). Additionally, MMP-9 activity increased in MDA-MB-231 treated cells at 24 h, while the activity level decreased at 48 h post calcitriol treatment (Figure 3D).
Figure 3 Quantitative analysis using ELISA to measure MMP-2 and MMP-9 activities. Enzymatic activity was measured using ELISA in MCF-7 (A, C) and MDA-MB-231 (B, D) cells following 10 µM of calcitriol treatment. (** and ***) represents statistically significant change (p < 0.05 and p < 0.001) in MMP-2 and MMP-9 enzymatic activity between treated and control (Ctrl) untreated cells at given time points.
Vitamin D Disrupts the Activity of Pro-Vasculogenic Mimicry Regulators
Intending to evaluate the effect of vitamin D on VM mechanism, we investigated the regulators of pro-VM, by Proteome Profiler array analysis, which affirmed that vitamin D treatment has remarkably reduced the levels of fundamental pro-VM regulators in MCF-7 and MDA-MB-231 cells. A significant reduction of VEGF was observed in MCF-7 and MDA-MB-231 cells posttreatment (Figure 4A). Additionally, the TGF-β1 level was also significantly reduced in both cell lines compared to the control (Figure 4B). Moreover, there was a significant reduction of urokinase-type plasminogen activator (uPA) level that was more consequential in MCF-7 cells in distinction to MDA-MB-231 cells (Figure 4C), as the level of amphiregulin decreased in both MCF-7 cells and MDA-MB-231 cells, but more significant reduction was observed in MCF-7 after treatment as compared to the control (Figure 4D). The panel of all VM regulating proteins is shown in Supplementary Figure 1.
Figure 4 VM Proteome Profiler array analysis in MCF-7 and MDA-MB-231 cells after calcitriol treatment. VEGF (A) and TGF-β1 (B), urokinase-type plasminogen activator (uPA) (C), and amphiregulin (D) protein levels in MCF-7 and MDA-MB-231 cells following calcitriol treatment. (***p < 0.001) represents statistically significant change in protein levels between treated and control (Ctrl) untreated cells at given time points.
The Impact of Vitamin D on Cell Migration and Invasion
To discern the impact of vitamin D on the dynamics of cell migration and cell invasion, we quantified the migration/invasion of untreated and treated MCF-7 and MDA-MB-231 cells (Figures 5A, B). Both cell lines MCF-7 and MDA-MB-231 displayed a significant reduction in the migration level after vitamin D treatment (Figure 5A). Furthermore, calcitriol treatment inhibited the invasion ability of both cell lines, with the MDA-MB-231 cell line displaying a significant reduction in the number of invading cells (Figure 5B).
Figure 5 Migration and invasion of MCF-7 and MDA-MB-231 cells after calcitriol treatment. (A) Cell migration assay displays the reduction of the number of migrating cells in both MCF-7 and MDA-MB-231 cells after treatment with calcitriol (10 µM). Cell invasion assay displays the reduction of the number of migrating cells in both MCF-7 and MDA-MB-231 cells after treatment with calcitriol (10 µM). (**), (***) represents statistically significant change (p < 0.05) and (p < 0.001), respectively in number of cells between treated and control (Ctrl) untreated cells at given time points.
The Effect of Vitamin D on Vasculogenic Mimicry Formation
We next performed the tubular-structure initiation assay, as an established in vitro assay for VM formation, in the MDA-MB-231 and MCF-7 cells in the control and treated groups (Figure 6). The Matrigel-based assay was performed to acquire the evidence of VM by analyzing the tube formation in the seed cells. This showed a reduced number and mass of MDA-MB-231 and MCF-7 cells when treated with calcitriol (Figure 6A). Furthermore, the tubular-structure formation was significantly decreased in the aggressive triple-negative MDA-MB-231 cells in comparison to the control counterparts (Figure 6B).
Figure 6 The effect of calcitriol treatment on tube formation assay in MCF-7 and MDA-MB-231 cells after calcitriol treatment. (A) Reduction of the cell mass of both MCF-7 and MDA-MB-231 cells after treatment with calcitriol (10 µM). (B) Significant inhibition of tube formation in MDA-MB-231 cells after treatment with calcitriol. (***) represents statistically significant change (p < 0.001) in number of cells between treated and control (Ctrl) untreated cells at given time points.
Discussion
VM is a novel tumor vascular model that explicitly underpins the ability of aggressive cancer cells to form vessel-like networks that supply sufficient blood supply for tumor growth. VM induction is mediated by several molecular mechanisms and signaling pathways. Cancer stem cells (CSCs) and epithelial–mesenchymal transitions have also been linked to VM formation. VM is associated with tumor invasion, metastasis, and poor oncological outcomes. Because of the importance of VM in tumor progression, more VM-related anticancer strategies are being adopted in the medical field. Our study illustrates the VM properties of vitamin D in BC cells as vitamin D treatment induced TIMP1 and TIMP2 expression levels and reduced MMP-2 and MMP-9 catalytic activities. Similarly, the VEGF and TGF-β1 protein contents were significantly downregulated in both groups of BC cells. Overall, the migration and invasion potential were substantially downregulated by vitamin D treatment in BC cells. In addition, vitamin D reduced the cell mass and VM formation in both groups of BC cells. Finally, MMPs are essential for tumor invasion, metastasis, and VM formation.
A fundamental prerequisite for VM formation is the expression of high levels of MMPs. MMPs cleave Laminin5γ2 into 5γ2x and 5γ2′ for dense extracellular matrix protein deposition, resulting in the formation of de novo blood vessels in solid tumors (50). Type IV collagens are the primary building blocks of the extracellular matrix and basement membrane. Tumor cells can primarily express MMP-2 and MMP-9 to debase type IV collagens and disrupt these tissue barriers, which stimulates tumor cell invasion and metastasis (51). TIMPs inhibit MMP activity, which is required for extracellular matrix turnover in both physiologic and pathologic tissue remodeling. In addition to inhibiting MMP, they are associated with other biological systems needed for metastasis and VM (52). In this context, our study has investigated the non-neoplastic functions of vitamin D on TIMP/MMP systems that stimulate cell invasion and migration in BC. Our study findings report that MCF-7 and MDA-MB-231 cells treated with calcitriol (10 µM) resulted in increased levels of TIMP1 and TIMP2 that were most apparent after treatment for 24 h. In contrast, MCF-7 and MDA-MB-231 cells treated with calcitriol (10 µM) resulted in decreased levels of MMP-2 and MMP-9. The VEGF signaling is a key modulator of VM (53). In ovarian cancer, VEGF-A has been linked to VM formation by elevating the expression of MMP-9, MMP-2, VE-cadherin, and EphA2. The VEGFR-2 is abundantly expressed in vascular ECs, resulting in vasculogenesis. VEGFR-1, on the other hand, is overexpressed in VM-forming tumor cells in malignant melanoma (54). The elevated levels of VEGF and VEGFR-1, as well as MMP-9 and MMP-2, have been linked to the formation of VM in gastric cancer tissues (55). VEGF signaling further activates the PI3K/PKC and ERK signaling pathways, resulting in cell migration, invasion, and proliferation (56, 57). In breast and pancreatic cancer, inhibiting EphA2 reduces VEGF expression with the resultant angiogenesis in vivo. This finding lends credence to the theory that VEGF signaling is the activating event in VM formation (58, 59). Increased VEGFR-2 expression has been correlated with VM formation in tumors derived from CSCs and glioma stem-like cells (60, 61). A recent study demonstrated that siRNA-based VEGF gene silencing reduced cell migration, invasion, and proliferation in choroidal melanoma. VEGF inhibition reduced the expression of MMPs, AKT, p-AKT, MMP-9, and MMP-2, and thus the formation of VM was reduced through the PI3K/AKT signaling pathway (62).
Research has shown that TGF-β regulates cell cycle, cell proliferation, motility, invasion, and apoptosis (63). TGF-β can either stimulate or inhibit cancer progression in a variety of cancers. Endoglin (CD105), a TGF-β co-receptor, has been shown to induce VM formation and neo-angiogenesis in Ewing’s sarcoma (64). In a study, TGF-β was inactivated by silencing TGF-R1, with the associated reduction in the expression of MMP-2, VE-cadherin. In glioma, inhibiting the TGF-β signaling pathway reduces the expression of MMP-14 and MT1-MMP, leading to a significant decrement in the formation of VM (65, 66). Previous studies have established the role of VEGF (67), TGF-β1 (61), uPA (68), and amphiregulin (69) in VM formation in cancer. Vitamin D has anti-VM ramifications by decreasing the expression of VM growth factors in tumor cells’ VEGF (70). Consequently, in our study, we have elucidated the anti-VM potential of vitamin D in BC by reducing the level of VEGF. This finding is grounded by a reduction of fundamental pro-VM regulators VEGF, TGF-β1, and uPA, in addition to amphiregulin in MCF-7 and MDA-MB-231 cells treated with calcitriol (10 µM).
In patients with malignant tumors, VM is significantly correlated with elevated tumor grade, invasion, metastasis, and a poor prognosis (71, 72). VM emerges in a wide range of cancer tissues including aggressive melanomas (73), breast cancer (74), ovarian cancer (75), prostate cancer (76), lung cancer (77), liver cancer (78), and glioblastoma (79). The tumors with a high degree of overall VM showcase poor prognosis (80), as VM also correlates with tumor staging (81). Tumor cells that engage in VM exhibit elevated cancer stemness and endothelial-like gene expression. Tumor cells are directly adjacent to blood flow during the development of vascular mimetic vessels, increasing the likelihood of detachment and intrastation of these cells to distant sites (82). In our study, we evaluated the levels of cell migration and invasion following the vitamin D treatment of both cell lines MCF-7 and MDA-MB-231. The results depicted a clear reduction of migrating and invading cells. Human BC tumors are essentially categorized according to the clinicopathological and histopathologic characteristics along with their molecular markers. TNBC and HER2 are widely regarded as the most aggressive phenotypes of BC. The relationship between VM and breast tumor phenotype has been widely studied. In vitro studies have revealed that TNBC aggressive cells, as opposed to more differentiated BC cells, are more susceptible to forming tubular structures (83). Several studies have reported that TNBC MDA-MB-231 and HCC1937 cells readily form tubular-like structures (11, 84). In contrast, the ER-positive cell line MCF-7 has been shown to be incapable of forming VM (16), but in the availability of VM drivers such as interleukin 1, MCF-7 cells formed microvessel-like intersections and cords (7). Accordingly, we further investigated the effect of vitamin D on VM formation in the vitamin D-treated MDA-MB-231 and MCF-7 cells. Both cell lines exhibited a reduction in the cell mass; in addition, the tubular-structure formation was substantially reduced in the aggressive MDA-MB-231 cells. VM triggers tumor growth, progression, metastasis, invasion, and treatment failure. Numerous studies (85–87) reported that patients with VM-positive tumors have a worse prognosis and a poor 5-year survival rate than patients with VM-negative tumors. The prevalence of VM positivity, as well as its influence on clinicopathological parameters and prognosis in BC patients, has been extensively researched over the last two decades (88–90). The current body of literature affirms a negative correlation between VM and the reported clinical oncological outcomes. There is now concrete evidence that the formation of VM is a significant impediment to anti-angiogenic therapy. Admittedly, inducing hypoxia may endorse VM, which in turn promotes distant metastasis (91, 92). In a study of triple-negative BC cells, the influence of anti-angiogenic treatment on VM promotion was confirmed (93). Thus, cells treated with sunitinib (a VEGFR tyrosine kinase inhibitor) showed an increase in VM-positive cases when compared to control cells. Overexpression of HIF-1, VE-cadherin, and Twist1 was found to be responsible for these effects (93). A recent study used trastuzumab, a drug that engages the receptor tyrosine kinase HER2 in BC cells (94). Numerous VM markers were highly expressed in trastuzumab-treated cells, indicating that trastuzumab-resistant HER-2-positive BC cells can exhibit VM in an angiogenic microenvironment. As a result, VM may be recognized as one of the major causative factors of resistance to anti-angiogenic therapy in solid tumors. Conclusively, our study established a novel role of vitamin D in suppressing VM in BC cells.
Conclusion
Our study provides compelling evidence that the antitumor and anti-VM roles of vitamin D is mediated by reducing the VM growth factor levels and by altering TIMP/MMP systems in BC. These antitumor effects of vitamin D ultimately have the potential to reduce the risk of tumor cell migration and invasion. Moreover, our study findings provide a translational significance of utilizing vitamin D (25-hydroxyvitamin D (25(OH)D) or calcitriol) as a supplementary anticancer agent.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Author Contributions
Conceptualization: KB. Data curation: KB, AA-A, LS, MS-A, and ASa. Investigation: KB, AA-A, MS-A, LS, JS, ASa, Ash, WE, JM, SG, and MH. Supervision: KB. Writing—original draft: KB, AAA, MS-A, and LS. Writing—review and editing: KB, AE, and SG. All authors agree to be accountable for all aspects of the work.
Funding
This work was supported by the University of Sharjah Seed grant, Ref. number: 1901090150.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
We would like to acknowledge the generous support of the Sharjah Institute for Medical Research (SIMR), University of Sharjah, UAE. The abstract of this paper was presented at the American Association for Cancer Research (AACR) Annual virtual Meeting, 2020, USA, as an online abstract with interim findings. The abstract was published in Cancer Research 80 (16 Supplement), 5030-5030 of the AACR annual meeting website. DOI: 10.1158/1538-7445.AM2020-5030 Published August 2020.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.918340/full#supplementary-material
Supplementary Figure 1 | Images of the nitrocellulose proteome profiler membrane showing differences in the protein expression of Pro-VM formation mediators in the control and treated samples, (A) MCF-7 and (B) MDA-MB-231.
Supplementary Table 1 | Key VM-related genes and signaling pathways in Breast cancer cells that are differentially regulated by Vitamin D signaling. The adjusted p-value, odds ratio, and the combined score are shown for each pathway.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries Global Cancer Statistics. J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492
2. Ji P, Gong Y, Jin ML, Hu X, Di GH, Shao ZM. The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels. Front Oncol (2020) 10:650. doi: 10.3389/fonc.2020.00650
3. Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular Biology in Breast Cancer: Intrinsic Subtypes and Signaling Pathways. Cancer Treat Rev (2012) 38(6):698–707. doi: 10.1016/j.ctrv.2011.11.005
4. EA R, Ellis IO. Modern Classification of Breast Cancer: Should We Stick With Morphology or Convert to Molecular Profile Characteristics. Adv Anat Pathol (2011) 18(4):255–67. doi: 10.1097/PAP.0b013e318220f5d1
5. Jue C, Zhifeng W, Zhisheng Z, Lin C, Yayun Q, Feng J, et al. Vasculogenic Mimicry in Hepatocellular Carcinoma Contributes to Portal Vein Invasion. Oncotarget (2016) 7(47):77987–97. doi: 10.18632/oncotarget.12867
6. Tong M, Han BB, Holpuch AS, Pei P, He L, Mallery SR. Inherent Phenotypic Plasticity Facilitates Progression of Head and Neck Cancer: Endotheliod Characteristics Enable Angiogenesis and Invasion. Exp Cell Res (2013) 319(7):1028–42. doi: 10.1016/j.yexcr.2013.01.013
7. Nisar MA, Zheng Q, Saleem MZ, Ahmmed B, Ramzan MN, Ud Din SR, et al. IL-1β Promotes Vasculogenic Mimicry of Breast Cancer Cells Through P38/MAPK and PI3K/Akt Signaling Pathways. Front Oncol (2021) 11:113. doi: 10.3389/fonc.2021.618839
8. Morales-Guadarrama G, García-Becerra Rocío, Méndez-Pérez EA, García-Quiroz J, Avila E, Díaz L, et al. (2021) 10(7):1758. Cells.
9. Wagenblast E, Soto M, Gutierrez-Angel S, Hartl CA, Gable AL, Maceli AR, et al. A Model of Breast Cancer Heterogeneity Reveals Vascular Mimicry as a Driver of Metastasis. Nature (2015) 520:358–62. doi: 10.1038/nature14403
10. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in Cancer. Vasc Health Risk Manage (2006) 2:213–9. doi: 10.2147/vhrm.2006.2.3.213
11. Quiros-Gonzalez I, Tomaszewski MR, Aitken SJ, Ansel-Bollepalli L, McDuffus LA, Gill M, et al. Optoacoustics Delineates Murine Breast Cancer Models Displaying Angiogenesis and Vascular Mimicry. Br J Cancer (2018) 118:1098–106. doi: 10.1038/s41416-018-0033-x
12. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular Channel Formation by Human Melanoma Cells In Vivo and In Vitro: Vasculogenic Mimicry. Am J Pathol (1999) 155:739–52. doi: 10.1016/S0002-9440(10)65173-5
13. Jafarian AH, Kooshkiforooshani M, Rasoliostadi A, Mohamadian Roshan N. Vascular Mimicry Expression in Invasive Ductal Carcinoma; A New Technique for Prospect of Aggressiveness. Iran. J Pathol (2019) 14:232–5. doi: 10.30699/ijp.2019.94997.1939
14. Soares R, Reis-Filho JS, Gartner F, Schmitt FC, Iruela-Arispa L, Graubert MD. Vascular Endothelial Growth Factor, Transforming Growth Factor-α, and Estrogen Receptors: Possible Cross-Talks and Interactions. Am J Pathol (2002) 160:381–3. doi: 10.1016/S0002-9440(10)64381-7
15. Lee KS, Shin JS, Shon YH, Nam KS. Anti-Angiogenic Activity in Metastasis of Human Breast Cancer Cell Irradaited by a Proton Beam. J Korean Phys Soc (2012) 61:268–72. doi: 10.3938/jkps.61.268
16. Luan YY, Liu ZM, Zhong JY, Yao RY, Yu HS. Effect of Grape Seed Proanthocyanidins on Tumor Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cells. Asian Pac. J Cancer Prev (2015) 16:531–5. doi: 10.7314/apjcp.2015.16.2.531.
17. Zhang R, Naughton DP. Vitamin D in Health and Disease: Current Perspectives. Nutr J (2010) 9:65. doi: 10.1186/1475-2891-9-65
18. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer H F, et al. Vitamin D and Human Health: Lessons From Vitamin D Receptor Null Mice. Endocr Rev (2008) 29(6):726–76. doi: 10.1210/er.2008-0004
19. Diesing D, Cordes T, Fischer D, Diedrich K, Friedrich M. Vitamin D–metabolism in the Human Breast Cancer Cell Line MCF-7. Anticancer Res (2006) 26:2755–9.
20. Carlberg C. Current Understanding of the Function of the Nuclear Vitamin D Receptor in Response to its Natural and Synthetic Ligands. Recent Results Cancer Res (2003) 164:29–42. doi: 10.1007/978-3-642-55580-0_2
21. Evans R M. The Steroid and Thyroid Hormone Receptor Superfamily. Science (1988) 240(4854):889–95. doi: 10.1126/science.3283939
22. Zehnder D, Bland R, Williams M C, McNinch R W, Howie A J, Stewart P M, et al. Extrarenal Expression of 25-Hydroxyvitamin D(3)-1 Alpha-Hydroxylase. J Clin Endocrinol Metab (2001) 86(2):888–94. doi: 10.1210/jcem.86.2.7220
23. Welsh and J. Targets of Vitamin D Receptor Signaling in the Mammary Gland. J Bone Miner Res (2007), 22(Suppl 2):V86–90. doi: 10.1359/jbmr.07s204
24. Townsend K, Evans K N, Campbell M J, Colston K W, Adams J S, Hewison M. Biological Actions of Extra-Renal 25-Hydroxyvitamin D-1α-Hydroxylase and Implications for Chemoprevention and Treatment. J Steroid Biochem Mol Biol (2005) 97(1-2):103–9. doi: 10.1016/j.jsbmb.2005.06.004
25. Jensen S S, Madsen M W, Lukas J, Binderup L, Bartek J. Inhibitory Effects of 1alpha,25-Dihydroxyvitamin D(3) on the G(1)-S Phase-Controlling Machinery. Mol Endocrinol (2001) 15(8):1370–80. doi: 10.1210/mend.15.8.0673
26. Simboli-Campbell M, Narvaez C J, van Weelden K, Tenniswood M, Welsh J. Comparative Effects of 1,25(OH)2D3 and EB1089 on Cell Cycle Kinetics and Apoptosis in MCF-7 Breast Cancer Cells. Breast Cancer Res Treat (1997) 42(1):31–41. doi: 10.1023/A:1005772432465
27. Colston K W, Hansen C M. Mechanisms Implicated in the Growth Regulatory Effects of Vitamin D in Breast Cancer. Endocr Relat Cancer (2002) 9(1):45–59. doi: 10.1677/erc.0.0090045
28. James S Y, Mackay A G, Colston K W. Effects of 1,25 Dihydroxyvitamin D3 and its Analogues on Induction of Apoptosis in Breast Cancer Cells. Steroid Biochem Mol Biol (1996) 58(4):395–401. doi: 10.1016/0960-0760(96)00048-9
29. Ooi L L, Zhou H, Kalak R, Zheng Y, Conigrave A D, Seibel M J, et al. Vitamin D Deficiency Promotes Human Breast Cancer Growth in a Murine Model of Bone Metastasis. Cancer Res (2010) 70(5):1835–44. doi: 10.1158/0008-5472.CAN-09-3194
30. Wang Q, Lee D, Sysounthone V, Chandraratna R A S, Christakos S, Korah R, et al. 1,25-Dihydroxyvitamin D3 and Retonic Acid Analogues Induce Differentiation in Breast Cancer Cells With Function- and Cell-Specific Additive Effects. Breast Cancer Res Treat (2001) 67(2):157–68. doi: 10.1023/A:1010643323268
31. Koli K, Keski-Oja J. 1α,25-Dihydroxyvitamin D3 and its Analogues Down-Regulate Cell Invasion-Associated Proteases in Cultured Malignant Cells. Cell Growth Differ (2000) 11(4):221–9.
32. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D. Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy. Endocrinology (2010) 15(1):32–42. doi: 10.1210/en.2009-0855
33. James SY, Mackay AG, Binderup L, Colston KW. Effects of a New Synthetic Vitamin D Analogue, EB1089, on the Oestrogen-Responsive Growth of Human Breast Cancer Cells. Endocrinol (1994) 141(3):555–63. doi: 10.1677/joe.0.1410555
34. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB. Regulation of Estrogen Receptor-Alpha Gene Expression by 1, 25-Dihydroxyvitamin D in MCF-7 Cells. Cell Biochem (1999) 75(4):640–51. doi: 10.1002/(SICI)1097-4644(19991215)75:4<640::AID-JCB10>3.0.CO;2-8
35. Ma Y, Trump DL, Johnson CS. Vitamin D in Combination Cancer Treatment. J Cancer (2010) 1:101–7. doi: 10.7150/jca.1.101
36. Mehta RG, Peng X, Alimirah F, Murillo G, Mehta R. Vitamin D and Breast Cancer: Emerging Concepts. Cancer Lett (2013) 334(1):95–100. doi: 10.1016/j.canlet.2012.10.034
37. Trump DL. Calcitriol and Cancer Therapy: A Missed Opportunity. Bone Rep (2018) 9:110–9. doi: 10.1016/j.bonr.2018.06.002
38. Diaz L, Diaz-Munoz M, Garcia-Gaytan AC, Mendez I. Mechanistic Effects of Calcitriol in Cancer Biology. Nutrients (2015) 7:5020–50. doi: 10.3390/nu7065020
39. Shan NL, Wahler J, Lee HJ, Bak MJ, Gupta SD, Maehr H, et al. Vitamin D Compounds Inhibit Cancer Stem-Like Cells and Induce Differentiation in Triple Negative Breast Cancer. J Steroid Biochem Mol Biol (2017) 173:122–9. doi: 10.1016/j.jsbmb.2016.12.001
40. Thill M, Reichert K, Woeste A, Polack S, Fischer D, Hoellen F, et al. Combined Treatment of Breast Cancer Cell Lines With Vitamin D and COX-2 Inhibitors. Anticancer Res (2015) 35(2). doi: 10.1097/PAP.0b013e318220f5d1
41. Bajbouj K, Sahnoon L, Shafarin J, Al-Ali A, Muhammad JS, Karim A, et al. Vitamin D-Mediated Anti-Cancer Activity Involves Iron Homeostatic Balance Disruption and Oxidative Stress Induction in Breast Cancer. Front Cell Dev Biol (2021) 9:766978. doi: 10.3389/fcell.2021.766978
42. Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, Barettino D, et al. 1alpha,25-Dihydroxyvitamin D3 Regulates the Expression of Id1 and Id2 Genes and the Angiogenic Phenotype of Human Colon Carcinoma Cells. Oncogene (2005) 24:6533–44. doi: 10.1038/sj.onc.1208801
43. Grundmann M, Haidar M, Placzko S, Niendorf R, Darashchonak N, Hubel CA, et al. Vitamin D Improves the Angiogenic Properties of Endothelial Progenitor Cells. Am J Physiol Cell Physiol (2012) 303:C954–62. doi: 10.1152/ajpcell.00030.2012
44. Lin R, Amizuka N, Sasaki T, Aarts MM, Ozawa H, Goltzman D, et al. 1Alpha,25-Dihydroxyvitamin D3 Promotes Vascularization of the Chondro-Osseous Junction by Stimulating Expression of Vascular Endothelial Growth Factor and Matrix Metalloproteinase 9. J Bone Miner Res (2002) 17:1604–12. doi: 10.1359/jbmr.2002.17.9.1604
45. Yamamoto T, Kozawa O, Tanabe K, Akamatsu S, Matsuno H, Dohi S, et al. 1,25-Dihydroxyvitamin D3 Stimulates Vascular Endothelial Growth Factor Release in Aortic Smooth Muscle Cells: Role of P38 Mitogen-Activated Protein Kinase. Arch Biochem Biophys (2002) 398:1–6. doi: 10.1006/abbi.2001.2632
46. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative Effects of 1alpha,25-Dihydroxyvitamin D(3) and Vitamin D Analogs on Tumor-Derived Endothelial Cells. Endocrinology (2002) 143:2508–14. doi: 10.1210/endo.143.7.8887
47. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 Alpha,25-Dihydroxyvitamin D(3) Inhibits Angiogenesis In Vitro and In Vivo. Circ Res (2000) 87:214–20. doi: 10.1161/01.RES.87.3.214
48. García-Quiroz J, García-Becerra R, Santos-Cuevas C, Ramírez-Nava GJ, Morales-Guadarrama G, Cárdenas-Ochoa N, et al. Synergistic Antitumorigenic Activity of Calcitriol With Curcumin or Resveratrol is Mediated by Angiogenesis Inhibition in Triple Negative Breast Cancer Xenografts. Cancers (2019) 11:1739. doi: 10.3390/cancers11111739
49. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: Interactive and Collaborative HTML5 Gene List Enrichment Analysis Tool. BMC Bioinformatics (2013) 14:128. doi: 10.1186/1471-2105-14-128
50. Wechman SL, Emdad L, Sarkar D, Das SK, Fisher PB. Vascular Mimicry: Triggers, Molecular Interactions and In Vivo Models. Adv Cancer Res (2020) 148:27–67. doi: 10.1016/bs.acr.2020.06.001
51. Li H, Qiu Z, Li F, Wang C. The Relationship Between MMP-2 and MMP-9 Expression Levels With Breast Cancer Incidence and Prognosis. Oncol Lett (2017) 14(5):5865–70. doi: 10.3892/ol.2017.6924
52. Sun J. Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases are Essential for the Inflammatory Response in Cancer Cells. Signal Transduct (2010) 2010:985132. doi: 10.1155/2010/985132
53. Paulis YWJ, Soetekouw PMMB, Verheul HMW, Tjan-Heijnen VCG, Griffioen AW. Signalling Pathways in Vasculogenic Mimicry. Biochim Biophys Acta (BBA) - Rev Cancer (2010) 1806(1):18–28. doi: 10.1016/j.bbcan.2010.01.001
54. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, et al. VEGFR-1 Expressed by Malignant Melanoma-Initiating Cells is Required for Tumor Growth. Cancer Res (2011) 71(4):1474–85. doi: 10.1158/0008-5472.can-10-1660
55. Lv J, Sun B, Sun H, Zhang Y, Sun J, Zhao X, et al Signifcance of Vasculogenic Mimicry Formation in Gastric Carcinoma. Oncol Res Treat (2017) 40(1–2):35–41. doi: 10.1159/000455144
56. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal Transduction by Vascular Endothelial Growth Factor Receptors. Biochem J (2011) 437(2):169–83. doi: 10.1042/bj20110301
57. Vartanian A, Stepanova E, Grigorieva I, Solomko E, Baryshnikov A, Lichinitser M. VEGFR1 and PKCalpha Signaling Control Melanoma Vasculogenic Mimicry in a VEGFR2 Kinase-Independent Manner. Melanoma Res (2011) 21(2):91–8. doi: 10.1097/CMR.0b013e328343a237
58. Lugano R, Ramachandran M, Dimberg A. Tumor Angiogenesis: Causes, Consequences, Challenges and Opportunities. Cell Mol Life Sci (2019) 77(9):1–26. doi: 10.1007/s00018-019-03351-7
59. Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J. Ephrin-A1 Facilitates Mammary Tumor Metastasis Through an Angiogenesis-Dependent Mechanism Mediated by EphA Receptor and Vascular Endothelial Growth Factor in Mice. Cancer Res (2006) 66(21):10315–24. doi: 10.1158/0008-5472.can-06-1560
60. Biondani G, Zeeberg K, Greco MR, Cannone S, Dando I, Dalla Pozza E, et al. Extracellular Matrix Composition Modulates PDAC Parenchymal and Stem Cell Plasticity and Behavior Through the Secretome. FEBS J (2018) 285(11):2104–24. doi: 10.1111/febs.14471
61. Yao X, Ping Y, Liu Y, Chen K, Yoshimura T, Liu M, et al. Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Plays a Key Role in Vasculogenic Mimicry Formation, Neovascularization and Tumor Initiation by Glioma Stem-Like Cells. PLoS One (2013) 8(3):e57188–8. doi: 10.1371/journal.pone.0057188
62. Xu X, Zong Y, Gao Y, Sun X, Zhao H, Luo W, et al. VEGF Induce Vasculogenic Mimicry of Choroidal Melanoma Through the PI3K Signal Pathway. BioMed Res Int (2019) 2019:3909102. doi: 10.1155/2019/3909102
64. Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordonez JL, et al. Preclinical Efcacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma. Clin Cancer Res Of J Am Assoc Cancer Res (2019) 25(7):2228–40. doi: 10.1158/1078-0432.ccr-18-0936
65. Ling G, Wang S, Song Z, Sun X, Liu Y, Jiang X, et al. Transforming Growth Factor-β is Required for Vasculogenic Mimicry Formation in Glioma Cell Line U251MG. Cancer Biol Ther (2011) 12(11):978–88. doi: 10.4161/cbt.12.11.18155
66. Ling G, Ji Q, Ye W, Ma D, Wang Y. Epithelial–mesenchymal Transition Regulated by P38/MAPK Signaling Pathways Participates in Vasculogenic Mimicry Formation in SHG44 Cells Transfected With TGF-Beta cDNA Loaded Lentivirus In Vitro and In Vivo. Int J Oncol (2016) 49(6):2387–98. doi: 10.3892/ijo.2016.3724
67. Wang JY, Sun T, Zhao XL, Zhang SW, Zhang DF, Gu Q, et al. Functional Significance of VEGF-A in Human Ovarian Carcinoma: Role in Vasculogenic Mimicry. Cancer Biol Ther (2008) 7(5):758–66. doi: 10.4161/cbt.7.5.5765
68. Yang Z, Sun B, Li Y, Zhao X, Zhao X, Gu Q, et al. ZEB2 Promotes Vasculogenic Mimicry by TGF-β1 Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma. Exp Mol Pathol (2015) 98(3):352–9. doi: 10.1016/j.yexmp.2015.03.030
69. Tang J, Wang J, Fan L, Li X, Liu N, Luo W, et al. cRGD Inhibits Vasculogenic Mimicry Formation by Down-Regulating uPA Expression and Reducing EMT in Ovarian Cancer. Oncotarget (2016) 7(17):24050–62. doi: 10.18632/oncotarget.8079
70. Awad AE, Ebrahim MA, Eissa LA, El-Shishtawy MM. Dickkopf-1 and Amphiregulin as Novel Biomarkers and Potential Therapeutic Targets in Hepatocellular Carcinoma. Int J Hematol Oncol Stem Cell Res (2019) 13(3):153–63. doi: 10.18502/ijhoscr.v13i3.1275
71. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-Dihydroxyvitamin D3 (Calcitriol) Inhibits Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway in Human Cancer Cells. Mol Cancer Ther (2007) 6(4):1433–9. doi: 10.1158/1535-7163.MCT-06-0677
72. Yang JP, Liao YD, Mai DM, Xie P, Qiang YY, Zheng LS, et al. Tumor Vasculogenic Mimicry Predicts Poor Prognosis in Cancer Patients: A Metaanalysis. Angiogenesis (2016) 19(2):191–200. doi: 10.1007/s10456-016-9500-2
73. Delgado-Bellido D, Serrano-Saenz S, Fernandez-Cortes M, Oliver FJ. Vasculogenic Mimicry Signaling Revisited: Focus on non-Vascular VE-Cadherin. Mol Cancer (2017) 16(1):65. doi: 10.1186/s12943-017-0631-x
74. Zhang Z, Imani S, Shasaltaneh MD, Hosseinifard H, Zou L, Fan Y, et al. The Role of Vascular Mimicry as a Biomarker in Malignant Melanoma: A Systematic Review and Meta-Analysis. BMC Cancer (2019) 19(1):1134. doi: 10.1186/s12885-019-6350-5
75. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of Endothelial Cells, Central Necrosis, and Fibrosis are Associated With Aggressive Inflammatory Breast Cancer. Cancer Res (2001) 61(2):445–51.
76. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, et al. Molecular Determinants of Ovarian Cancer Plasticity. Am J Pathol (2001) 158(4):1279–88. doi: 10.1016/S0002-9440(10)64079-5
77. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM Jr., Cohen MB, et al. Prostatic Tumor Cell Plasticity Involves Cooperative Interactions of Distinct Phenotypic Subpopulations: Role in Vasculogenic Mimicry. Prostate (2002) 50(3):189–201. doi: 10.1002/pros.10048
78. Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, et al. Vascular Phenotype in Angiogenic and non-Angiogenic Lung non-Small Cell Carcinomas. Br J Cancer (2002) 86(2):244–9. doi: 10.1038/sj.bjc.6600015
79. Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X, et al. Vasculogenic Mimicry is Associated With High Tumor Grade, Invasion and Metastasis, and Short Survival in Patients With Hepatocellular Carcinoma. Oncol Rep (2006) 16(4):693–8. doi: 10.3892/or.16.4.693
80. Yue WY, Chen ZP. Does Vasculogenic Mimicry Exist in Astrocytoma? J Histochem Cytochem (2005) 53(8):997–1002. doi: 10.1369/jhc.4A6521.2005
81. Sun B, Zhang S, Zhao X, Zhang W, Hao X. Vasculogenic Mimicry is Associated With Poor Survival in Patients With Mesothelial Sarcomas and Alveolar Rhabdomyo-Sarcomas. Int J Oncol (2004) 25(6):1609–14.
82. Lin P, Wang W, Sun BC, Cai WJ, Li L, Lu HH, et al. Vasculogenic Mimicry is a Key Prognostic Factor for Laryngeal Squamous Cell Carcinoma: A New Pattern of Blood Supply. Chin Med J (2012) 125(19):3445–9.
83. Izawa Y, Kashii-Magaribuchi K, Yoshida K, Nosaka M, Tsuji N, Yamamoto A, et al. Stem-Like Human Breast Cancer Cells Initiate Vasculogenic Mimicry on Matrigel. Acta HISTOCHEM ET CYTOCHEM (2018) 51(6):173–83. doi: 10.1267/ahc.18041
84. Pezzella F, Manzotti M, Di Bacco A, Viale G, Nicholson AG, Price R, et al. Evidence for Novel non-Angiogenic Pathway in Breast-Cancer Metastasis. Lancet (2000) 355(9217):1787–8.
85. Meng J, Chen S, Lei YY, Han JX, Zhong WL, Wang XR, et al. Hsp90beta Promotes Aggressive Vasculogenic Mimicry via Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Oncogene (2018) 38(2):228–43. doi: 10.1038/s41388-018-0428-4
86. Li Y, Wu Z, Yuan J, Sun L, Lin L, Huang N, et al. Long non-Coding RNA MALAT1 Promotes Gastric Cancer Tumorigenicity and Metastasis by Regulating Vasculogenic Mimicry and Angiogenesis. Cancer Lett (2017) 395:31–44. doi: 10.1016/j.canlet.2017.02.035
87. Yu W, Ding J, He M, Chen Y, Wang R, Han Z, et al. Estrogen Receptor Beta Promotes the Vasculogenic Mimicry (VM) and Cell Invasion via Altering the lncRNA-MALAT1/miR-145-5p/NEDD9 Signals in Lung Cancer. Oncogene (2019) 38(8):1225–38. doi: 10.1038/s41388-018-0463-1
88. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, et al. Vasculogenic Mimicry and Pseudo-Comedo Formation in Breast Cancer. Int J Cancer (2002) 99:821–8. doi: 10.1002/ijc.10423
89. Shen Y, Quan J, Wang M, Li S, Yang J, Lv M, et al. Tumor Vasculogenic Mimicry Formation as an Unfavorable Prognostic Indicator in Patients With Breast Cancer. Oncotarget (2017) 8:56408–16. doi: 10.18632/oncotarget.16919
90. Liu T, Sun B, Zhao X, Gu Q, Dong X, Yao Z, et al. HER2/neu Expression Correlates With Vasculogenic Mimicry in Invasive Breast Carcinoma. J Cell Mol Med (2013) 17:116–22. doi: 10.1111/j.1582-4934.2012.01653.x
91. Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-Term Anti-Vascular Endothelial Growth Factor Treatment Elicits Vasculogenic Mimicry Formation of Tumors to Accelerate Metastasis. J Exp Clin Cancer Res (2012) 31:1–7. doi: 10.1186/1756-9966-31-16
92. Valencia-Cervantes J, Huerta-Yepez S, Aquino-Jarquín G, Rodríguez-Enríquez S, Martínez-Fong D, Arias-Montaño JA, et al. Hypoxia Increases Chemoresistance in Human Medulloblastoma DAOY Cells via Hypoxia-Inducible Factor 1α-Mediated Downregulation of the CYP2B6, CYP3A4 and CYP3A5 Enzymes and Inhibition of Cell Proliferation. Oncol Rep (2019) 41:178–90. doi: 10.3892/or.2018.6790
93. Sun H, Zhang D, Yao Z, Lin X, Liu J, Gu Q, et al. Anti-Angiogenic Treatment Promotes Triple-Negative Breast Cancer Invasion via Vasculogenic Mimicry. Cancer Biol Ther (2017) 18:205–13. doi: 10.1080/15384047.2017.1294288
Keywords: vitamin D, breast cancer, invasion, vasculogenic mimicry, metalloproteinases
Citation: Bajbouj K, Al-Ali A, Shafarin J, Sahnoon L, Sawan A, Shehada A, Elkhalifa W, Saber-Ayad M, Muhammad JS, Elmoselhi AB, Guraya SY and Hamad M (2022) Vitamin D Exerts Significant Antitumor Effects by Suppressing Vasculogenic Mimicry in Breast Cancer Cells. Front. Oncol. 12:918340. doi: 10.3389/fonc.2022.918340
Received: 12 April 2022; Accepted: 09 May 2022;
Published: 07 June 2022.
Edited by:
Chao-Nan Qian, Sun Yat-sen University Cancer Center (SYSUCC), ChinaReviewed by:
Ming-Hsien Chan, Academia Sinica, TaiwanKai Li, Tianjin Medical University Cancer Institute and Hospital, China
Xuesong Yang, Jinan University, China
Copyright © 2022 Bajbouj, Al-Ali, Shafarin, Sahnoon, Sawan, Shehada, Elkhalifa, Saber-Ayad, Muhammad, Elmoselhi, Guraya and Hamad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Khuloud Bajbouj, S2JhamJvdWpAc2hhcmphaC5hYy5hZQ==